Computational study for suppression of CD25/IL-2 interaction

Dehbashi M., Hojati Z., Motovali-Bashi M., Ganjalikhani-Hakemi M., Shimosaka A., Cho W. C.

Biological Chemistry, cilt.402, sa.2, ss.167-178, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 402 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1515/hsz-2020-0326
  • Dergi Adı: Biological Chemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.167-178
  • Anahtar Kelimeler: CD25, de novo designed peptides, in silico, Off-target effects, siRNAs, virtual screened small molecules
  • İstanbul Medipol Üniversitesi Adresli: Hayır

Özet

Cancer recurrence presents a huge challenge in cancer patient management. Immune escape is a key mechanism of cancer progression and metastatic dissemination. CD25 is expressed in regulatory T (Treg) cells including tumor-infiltrating Treg cells (TI-Tregs). These cells specially activate and reinforce immune escape mechanism of cancers. The suppression of CD25/IL-2 interaction would be useful against Treg cells activation and ultimately immune escape of cancer. Here, software, web servers and databases were used, at which in silico designed small interfering RNAs (siRNAs), de novo designed peptides and virtual screened small molecules against CD25 were introduced for the prospect of eliminating cancer immune escape and obtaining successful treatment. We obtained siRNAs with low off-target effects. Further, small molecules based on the binding homology search in ligand and receptor similarity were introduced. Finally, the critical amino acids on CD25 were targeted by a de novo designed peptide with disulfide bond. Hence we introduced computational-based antagonists to lay a foundation for further in vitro and in vivo studies.